Examines TREM1 expression in microglia exposed to gp120, indicating a novel immune pathway in HIV infection.
Microglia serve as a long-lived reservoir for HIV in the brain and are resistant to the cytopathic effects of infection. As such, they pose a significant barrier to eradication strategies and contribute to chronic neuroinflammation in people living with HIV. We previously identified that triggering receptor expressed on myeloid cells-1 (TREM1) is upregulated in HIV-infected human microglia and is associated with resistance to virus-associated cellular stress. In this study, we examined the upstream mechanisms by which the HIV-1 envelope protein gp120 induces TREM1 expression in human monocyte-derived microglia. We found that gp120 induces TREM1 transcription through Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4) signalling, and that this process requires prostaglandin E₂ (PGE₂) signalling through prostaglandin E₂ receptor EP4. Inhibition of TREM1 increased apoptotic DNA fragmentation and cytotoxicity in gp120-exposed microglia, consistent with a functional contribution of TREM1 in modulating apoptotic signalling under these conditions. Together, these findings identify a TLR–PGE₂–TREM1 signalling axis that regulates innate immune responses and apoptotic marker modulation following HIV-1 envelope protein exposure. Given the contribution of long-lived microglia to HIV-associated neurocognitive disorders, the TREM1 pathway may represent a therapeutic target for modifying neuroinflammatory responses in the context of HIV infection.
No takes yet. Share an insight, caveat, or question.
Mahama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: